Allarity Therapeutics (ALLR) Competitors $0.94 +0.07 (+7.46%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$0.95 +0.00 (+0.36%) As of 08/22/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALLR vs. DRRX, BMEA, ANL, CGTX, BRNS, LTRN, IFRX, HOWL, UNCY, and DTILShould you be buying Allarity Therapeutics stock or one of its competitors? The main competitors of Allarity Therapeutics include DURECT (DRRX), Biomea Fusion (BMEA), Adlai Nortye (ANL), Cognition Therapeutics (CGTX), Barinthus Biotherapeutics (BRNS), Lantern Pharma (LTRN), InflaRx (IFRX), Werewolf Therapeutics (HOWL), Unicycive Therapeutics (UNCY), and Precision BioSciences (DTIL). These companies are all part of the "pharmaceutical products" industry. Allarity Therapeutics vs. Its Competitors DURECT Biomea Fusion Adlai Nortye Cognition Therapeutics Barinthus Biotherapeutics Lantern Pharma InflaRx Werewolf Therapeutics Unicycive Therapeutics Precision BioSciences Allarity Therapeutics (NASDAQ:ALLR) and DURECT (NASDAQ:DRRX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings, valuation and media sentiment. Is ALLR or DRRX more profitable? Allarity Therapeutics has a net margin of 0.00% compared to DURECT's net margin of -96.19%. Allarity Therapeutics' return on equity of -173.31% beat DURECT's return on equity.Company Net Margins Return on Equity Return on Assets Allarity TherapeuticsN/A -173.31% -102.57% DURECT -96.19%-259.16%-71.78% Which has more risk and volatility, ALLR or DRRX? Allarity Therapeutics has a beta of 0.08, suggesting that its share price is 92% less volatile than the S&P 500. Comparatively, DURECT has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500. Do analysts rate ALLR or DRRX? Allarity Therapeutics currently has a consensus target price of $9.00, indicating a potential upside of 852.78%. Given Allarity Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Allarity Therapeutics is more favorable than DURECT.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Allarity Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00DURECT 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Do insiders and institutionals have more ownership in ALLR or DRRX? 11.5% of Allarity Therapeutics shares are owned by institutional investors. Comparatively, 28.0% of DURECT shares are owned by institutional investors. 0.1% of Allarity Therapeutics shares are owned by company insiders. Comparatively, 3.2% of DURECT shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has stronger earnings and valuation, ALLR or DRRX? DURECT has higher revenue and earnings than Allarity Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAllarity TherapeuticsN/AN/A-$24.51MN/AN/ADURECT$2.03M29.37-$8.32M-$0.10-19.20 Does the media prefer ALLR or DRRX? In the previous week, DURECT had 3 more articles in the media than Allarity Therapeutics. MarketBeat recorded 3 mentions for DURECT and 0 mentions for Allarity Therapeutics. DURECT's average media sentiment score of 1.49 beat Allarity Therapeutics' score of 1.00 indicating that DURECT is being referred to more favorably in the news media. Company Overall Sentiment Allarity Therapeutics Positive DURECT Positive SummaryDURECT beats Allarity Therapeutics on 8 of the 13 factors compared between the two stocks. Get Allarity Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALLR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALLR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALLR vs. The Competition Export to ExcelMetricAllarity TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.85M$3.11B$5.76B$9.58BDividend YieldN/A2.23%4.41%4.10%P/E RatioN/A20.8831.1026.05Price / SalesN/A342.78433.22103.03Price / CashN/A43.1937.7358.48Price / Book1.148.129.536.61Net Income-$24.51M-$54.72M$3.26B$265.56M7 Day Performance-1.40%2.63%2.10%1.97%1 Month Performance-16.41%2.78%2.81%-0.36%1 Year Performance-82.78%11.01%30.56%19.03% Allarity Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALLRAllarity Therapeutics2.9852 of 5 stars$0.94+7.5%$9.00+852.8%-82.2%$12.85MN/A0.0010Positive NewsEarnings ReportDRRXDURECT2.2549 of 5 stars$1.87flatN/A+41.2%$58.05M$2.03M-12.4780Positive NewsBMEABiomea Fusion3.2444 of 5 stars$1.53-0.6%$16.80+998.0%-73.4%$57.86MN/A-0.5050ANLAdlai Nortye1.7821 of 5 stars$1.61+3.2%$9.00+459.0%-45.7%$57.56M$5M0.00127Gap UpCGTXCognition Therapeutics1.6903 of 5 stars$0.86+13.8%$2.83+230.0%+270.5%$55.44MN/A-1.2820Short Interest ↓BRNSBarinthus Biotherapeutics3.2304 of 5 stars$1.14-14.9%$6.25+448.2%-4.8%$54.06M$14.97M-0.66107Short Interest ↑LTRNLantern Pharma2.7017 of 5 stars$4.33-13.2%$25.00+477.4%+6.9%$53.82MN/A-2.3520Positive NewsIFRXInflaRx2.5698 of 5 stars$0.82+2.8%$6.60+701.9%-39.5%$53.72M$180K-1.0360News CoverageHOWLWerewolf Therapeutics3.2894 of 5 stars$1.18+0.9%$8.33+606.2%-40.0%$52.50M$1.88M-0.7140Analyst ForecastUNCYUnicycive Therapeutics2.642 of 5 stars$4.01-2.0%$60.00+1,396.3%+10.5%$51.70M$680K-0.799Trending NewsAnalyst DowngradeDTILPrecision BioSciences4.1627 of 5 stars$4.35-0.7%$47.00+980.5%-49.0%$51.63M$68.70M-0.49200Positive News Related Companies and Tools Related Companies DURECT Alternatives Biomea Fusion Alternatives Adlai Nortye Alternatives Cognition Therapeutics Alternatives Barinthus Biotherapeutics Alternatives Lantern Pharma Alternatives InflaRx Alternatives Werewolf Therapeutics Alternatives Unicycive Therapeutics Alternatives Precision BioSciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALLR) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allarity Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Allarity Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access